Arca
Skip to content
Tools
Tools

Relapsed or refractory solid tumors

Drug research and approvals for relapsed or refractory solid tumors: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 51 studies of relapsed or refractory solid tumors are recruiting on ClinicalTrials.gov, and Health Canada has authorized 12 drug trials for it since 2013.

  • Recruiting worldwide: 51
  • Trials authorized in Canada: 12
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 51 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

The 10 newest of 12; search them all in Canada trials
Nov 19, 2025A phase I study of GCAR1, a chimeric antigen receptor (CAR) T-cell therapy for participants with selected relapsed/refractory gpnmb-expressing solid tumoursGCAR1 / Fludarabine / CyclophosphamideCanadian Cancer Trials Group, Cancer Research Institute, Queen's UniversityOngoing
Jul 14, 2025A phase 1/2 trial of CBL0137 (nsc# 825802, ind# 155843) in patients with relapsed or refractory solid tumors including CNS tumors and lymphomaCBL0137Childrens Oncology GroupPending
Feb 19, 2025Phase I/II study of silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumorsSilmitasertib (CX-4945)Beat Childhood Cancer Research ConsortiumOngoing
Mar 20, 2024A phase I-ii, first-in-human study of SKB264 in patients with locally advanced unresectable /metastatic solid tumors who are refractory to available standard…SKB264 (MK-2870)Sichuan Kelun-Biotech Biopharmaceutical Co., LtdClosed
Mar 11, 2022A phase 1/ 2 study of bay 1895344 (elimusertib, ind#152153, nsc#810486) in pediatric patients with relapsed or refractory solid tumorsElimusertib (bay 1895344)Childrens Oncology GroupOngoing
Feb 10, 2020Phase 1 study of the bromodomain (BRD) and extra-terminal domain (BET) inhibitor BMS-986158 in pediatric cancerBMS-986158Dana Farber Cancer InstituteClosed
Nov 23, 2018A phase I, multicenter dose-escalation study to assess the tolerability, pharmacokinetics and preliminary anti-tumor activity of AZD5153 in patients with…AZD5153 / OlaparibAstraZeneca PharmaceuticalsClosed
Aug 10, 2018A phase 1 first-in-human study with ABBV-155 alone and in combination with taxane therapy in adults with relapsed and/or refractory solid tumorsABBV-155AbbVieClosed
Jul 6, 2017A phase I/II study of neratinib in pediatric patients with relapsed/ refractory solid tumorsNeratinibPediatric Oncology Experimental Therapeutic Investigator ConsortiumOngoing
Nov 13, 2014A phase 1/iia study of decitabine in combination with genistein in pediatric patients with relapsed or refractory solid tumors and leukemiaDecitabine / GenisteinCentre Hospitalier Universitaire Sainte-JustineClosed

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.